A Phase 2 interventional study of nilotinib in CML, sponsored by Novartis Pharmaceuticals. Completed at 54 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 31st largest by enrollment, is one of 11 that started in 2013, is one of 25 in phase 2, and was the 40th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 34th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2013, is one of 19 in phase 2, and was the 51st registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in patients who achieve MR4.5
Study protocol included criteria for study termination that was met when > 2 patients lost CCyR during TFR phase (> 1% BCR-ABL); This study was terminated early as > 2 cases of confirmed loss of complete cytogenetic response were reported despite BCR-ABL monitoring during the TFR Phase. All cases achieved MR4.5 after Nilotinib treatment re-initiation and maintained until end of study; trial did not mandate re-initiation within 4 weeks after loss of MMR_ that was a requirement in other Nilotinib TFR trials Initial sample size was 300 patients with CML-CP; Amendment #2 in June 2015 reduced sample size to 59 due to recruitment challenges; Study endpoint analysis and interpretations of data were challenging due to small sample size for early study closure..
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients entered a monitoring phase for 2 years and received 300 mg nilotinib mg bid. Patients who achieved MR4.5 entered a Consolidation Phase and were treated with nilotinib for 2 years. If MR4.5 was sustained during the Consolidation phase, patients were eligible to stop taking niltoinib during the treatment-free remission (TFR) phase.
Drug: nilotinib
Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
Also known as: AMN107
Percentage of Participants Without Molecular Relapse Within 6 Months After Starting the TFR Phase
Percentage of particpants without confirmed loss of MMR within 6 months following nilotinib TFR is calculated by dividing the number of patients with no documented confirmed loss of MR4, in the first 6 months after starting nilotinib TFR phase by the number of patients who entered nilotinib TFR phase. Molecular relapse is defined as having a confirmed BCR-ABL ratio above MMR (2 consecutive BCR-ABL levels \>0.1% IS taken approximately 4 weeks apart).
Time frame: 6 months after stopping nilotinib therapy
Relapse Free Survival is Defined as Time From the Date of Nilotinib Treatment Discontinuation to the First Documented Molecular Relapse (Confirmed Loss of MR4.5).
Relapse-free survival after the start of the TFR phase was summarized using the product-limit (Kaplan-Meier) estimates. The median for the relapse free survival and its 95% confidence intervals were provided. This analysis was performed on the FAS. Patients who dropped out without relapse were treated as censored observations.
Time frame: 7 years
Percentage of Participants Without Molecular Relapse Within 12 and 24 Months After Starting the Treatment -Free Remission (TFR) Phase
The percentage of participants without confirmed loss of MRR at 12 and 24 months is calculated by dividing the number of patients with no documented confirmed loss of MR4 at 12 and 24 months after starting the nilotinib TFR phase by the number of patients who entered nilotinib TFR phase.
Time frame: 12 and 24 months after starting the TFR
Percentage of Participants Who Regained MR4.5 After Restarting Nilotinib Due to Molecular Relapse
The percentage of participants who regained MR4.5 after restarting nilotinib will be calculated as the number of patients who achieved MR4.5 after having lost MR4 divided by the number of patients who lost MR4.
Time frame: Restart of nilotinib up to month 6, 12 and 24
Number of Participants Who Progressed to Accelerated Phase/Blastic Crisis (AP/BC) or Died From From Any Cause.
Progression to AP/BC and death where the "failure" event is the earliest occurrence of the following event: progression to AP/BC date.
Time frame: Baseline up to approximately 5 years
Overall Survival (OS)
OS was defined as the time from the date of cessation of nilotinib therapy to the date of death from any cause.
Time frame: Baseline up to approximately 5 years
Change in Symptom-burden Scores by the M.D. Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Assessment
The M.D. Anderson Symptom Inventory for CML patients (MDASI-CML) was used to assess the nature and impact of symptom burden on life. It consisted of 20 validated symptom items and 6 validated interference items. Each item was assessed on an 11 point scale with responses from 0-10, 0=not present and 10=as bad as you can imagine. Symptom score (SS) was calculated when a patient scored at least 8 items of the symptom items using the formula: (sum of scores for the items answered) / number of items answered. If a subject responded to \< 8 symptom items, the score was considered missing. Interference score (IS) was calculated when a patient scored at least 4 items using the formula: (sum of scores for the items answered)/number of items answered. If a subject responded to \< 4 interference items, the score was considered missing. The total symptom score was 0-200 and total interference score was 0-60. Mean change from baseline was summarized at all post-baseline time points
Time frame: From baseline to time to when MR4.5 is confirmed, up to 24 months, and from end of Consolidation Phase to 6 and 12 months into the TFR Phase
Change in Health Utility Assessed by EuroQol Group-5D-3L (EQ-5D-3L) Visual Analogue - Safety Set
The EQ-5D-3L questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and visual analog has a scale 0 to 100 (0=worst imaginable health state, 100=best imaginable health state).
Time frame: From baseline to time to when MR4.5, up to 24 months, is confirmed and from end of Consolidation Phase to 6 and 12 months into the TFR Phase
Change in Observed Scores for Patient Quality of Life Assessed by SF-8 - Safety Set
The SF-8 questionnaire consisted of 8 items (general health, physical functioning, role physical, bodily pain, vitality, social functioning, role-emotional and mental health) and was used to assess the impact of nilotinib treatment discontinuation on the quality of life. Each item had a 1 to 5 or 1 to 6 point response range and the higher number in the raw scores indicated poorer quality of life. The physical and mental component summary measures were calculated using a norm-based scoring method given in the instrument guidelines. These norm-based scores were summarized at baseline and mean change from baseline for post-baseline time points. The norm-based scores (based on the US population) had a mean of 50 and standard deviation of 10. Higher norm-based summary scores indicated better health
Time frame: From baseline to time to when MR4.5 is confirmed and from end of Consolidation Phase to 6 and 12 months into the TFR Phase
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 3 in Consolidation Phase - Safety Set
The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
Time frame: At month 3 in Consolidation Phase
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 12 in Consolidation Phase - Safety Set
The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
Time frame: Month 12 in Consolidation Phase
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 24 in Consolidation Phase - Safety Set
The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
Time frame: Month 24 in Consolidation Phase
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 6 in Treatment Free Remission Phase - Safety Set
The EuroQol Five Dimensional Three-level questionnaire (EQ-5D-3L) comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
Time frame: Month 6 in in Treatment Free Remission Phase
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 12 in Treatment Free Remission Phase - Safety Set
The EuroQol Five Dimensional Three-level questionnaire (EQ-5D-3L) comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
Time frame: Month 12 in in Treatment Free Remission Phase
| Milestone | Nilotinib |
|---|---|
| Started | 59 |
| Completed | 41 |
| Not completed | 18 |
| Withdrew: Adverse event | 4 |
| Withdrew: Abnormal laboratory value(s) | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 7 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Did not achieve mr4.5 | 1 |
| Milestone | Nilotinib |
|---|---|
| Started | 41 |
| Completed | 22 |
| Not completed | 19 |
| Withdrew: Adverse event | 2 |
| Withdrew: Unsatisfactory therapeutic effect | 4 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Administrative problems | 9 |
| Milestone | Nilotinib |
|---|---|
| Started | 32 |
| Completed | 32 |
| Not completed | 0 |
| Milestone | Nilotinib |
|---|---|
| Started | 17 |
| Completed | 4 |
| Not completed | 13 |
| Withdrew: Administrative problems | 10 |
| Withdrew: Adverse event | 1 |
| Withdrew: No longer required treatment | 1 |
| Withdrew: Withdrawal by subject | 1 |
Percentage of particpants without confirmed loss of MMR within 6 months following nilotinib TFR is calculated by dividing the number of patients with no documented confirmed loss of MR4, in the first 6 months after starting nilotinib TFR phase by the number of patients who entered nilotinib TFR phase. Molecular relapse is defined as having a confirmed BCR-ABL ratio above MMR (2 consecutive BCR-ABL levels \>0.1% IS taken approximately 4 weeks apart).
| Participants | Treatment Free Remission |
|---|---|
| Number of participants | 12 |
Relapse-free survival after the start of the TFR phase was summarized using the product-limit (Kaplan-Meier) estimates. The median for the relapse free survival and its 95% confidence intervals were provided. This analysis was performed on the FAS. Patients who dropped out without relapse were treated as censored observations.
| weeks | Treatment Free Remission |
|---|---|
| Relapse Free Survival is Defined as Time From the Date of Nilotinib Treatment Discontinuation to the First Documented Molecular Relapse (Confirmed Loss of MR4.5). | 21.4 (17.1 to NA) |
The percentage of participants without confirmed loss of MRR at 12 and 24 months is calculated by dividing the number of patients with no documented confirmed loss of MR4 at 12 and 24 months after starting the nilotinib TFR phase by the number of patients who entered nilotinib TFR phase.
| Participants | Treatment Free Remission |
|---|---|
| Month 12 — Number of participants | 8 |
| Month 24 — Number of participants | 2 |
The percentage of participants who regained MR4.5 after restarting nilotinib will be calculated as the number of patients who achieved MR4.5 after having lost MR4 divided by the number of patients who lost MR4.
| Participants | Treatment Free Remission |
|---|---|
| Month 6 — Number of participants | 7 |
| Month 12 — Number of participants | 17 |
| Month 24 — Number of participants | 17 |
Progression to AP/BC and death where the "failure" event is the earliest occurrence of the following event: progression to AP/BC date.
| participants | Treatment Free Remission |
|---|---|
| Number of Participants Who Progressed to Accelerated Phase/Blastic Crisis (AP/BC) or Died From From Any Cause. | 0 |
OS was defined as the time from the date of cessation of nilotinib therapy to the date of death from any cause.
| participants | Treatment Free Remission |
|---|---|
| Overall Survival (OS) | 0 |
The M.D. Anderson Symptom Inventory for CML patients (MDASI-CML) was used to assess the nature and impact of symptom burden on life. It consisted of 20 validated symptom items and 6 validated interference items. Each item was assessed on an 11 point scale with responses from 0-10, 0=not present and 10=as bad as you can imagine. Symptom score (SS) was calculated when a patient scored at least 8 items of the symptom items using the formula: (sum of scores for the items answered) / number of items answered. If a subject responded to \< 8 symptom items, the score was considered missing. Interference score (IS) was calculated when a patient scored at least 4 items using the formula: (sum of scores for the items answered)/number of items answered. If a subject responded to \< 4 interference items, the score was considered missing. The total symptom score was 0-200 and total interference score was 0-60. Mean change from baseline was summarized at all post-baseline time points
| scores on a scale | Treatment Free Remission |
|---|---|
| SS Baseline (observed value), n=40 | 0.125 ± 0.1314 |
| SS Consolidation Ph - M 3 (change from BL) n=26 | 0.012 ± 0.1362 |
| SS Consolidation Ph - M 12 (change from BL) n=30 | 0.021 ± 0.1140 |
| SS Consolidation Ph - M 24 (change from BL) n=26 | 0.026 ± 0.1402 |
| SS TFR Baseline (observed value) n=32 | 0.160 ± 0.1496 |
| SS TFR - Month 6 (change from BL) n=10 | -0.005 ± 0.1773 |
| SS TFR - Month 12 (change from BL) n=5 | -0.032 ± 0.1034 |
| IS Baseline (observed value), n=40 | 0.123 ± 0.2156 |
| IS Consolidation Ph - M 3 (change from BL) n=25 | 0.008 ± 0.1911 |
| IS Consolidation Ph - M 12 (change from BL) n=30 | -0.005 ± 0.1983 |
| IS Consolidation Ph - M 24 (change from BL) n=26 | 0.015 ± 0.1942 |
| IS TFR Baseline (observed value) n=32 | 0.141 ± 0.2067 |
| IS TFR - Month 6 (change from BL) n=10 | -0.015 ± 0.1780 |
| IS TFR - Month 12 (change from BL) n=5 | -0.037 ± 0.1880 |
The EQ-5D-3L questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and visual analog has a scale 0 to 100 (0=worst imaginable health state, 100=best imaginable health state).
| scores on scale | Treatment Free Remission |
|---|---|
| Baseline (observed value) | 83.250 (4.50 to 100.00) |
| Consolidation Ph - M 3 (change from BL) | 2.000 (-50.00 to 87.00) |
| Consolidation Ph - M 12 (change from BL) | 3.250 (-75.00 to 82.00) |
| Consolidation Ph - M 24 (change from BL) | 1.350 (-30.00 to 85.50) |
| TFR Baseline (observed value) | 80.00 (9.35 to 100.00) |
| TFR - Month 6 (change from BL) | 10.00 (-30.00 to 89.65) |
| TFR - Month 12 (change from BL) | 0.000 (-20.00 to 35.00) |
The SF-8 questionnaire consisted of 8 items (general health, physical functioning, role physical, bodily pain, vitality, social functioning, role-emotional and mental health) and was used to assess the impact of nilotinib treatment discontinuation on the quality of life. Each item had a 1 to 5 or 1 to 6 point response range and the higher number in the raw scores indicated poorer quality of life. The physical and mental component summary measures were calculated using a norm-based scoring method given in the instrument guidelines. These norm-based scores were summarized at baseline and mean change from baseline for post-baseline time points. The norm-based scores (based on the US population) had a mean of 50 and standard deviation of 10. Higher norm-based summary scores indicated better health
| scores on a scale | Treatment Free Remission |
|---|---|
| Baseline | 50.508 ± 8.4313 |
| Consolidation Ph - M 3 | 50.720 ± 7.6047 |
| Consolidation Ph - M 12 | 49.020 ± 10.1851 |
| Consolidation Ph - M 24 | 47.648 ± 8.7416 |
| TFR Baseline | 48.382 ± 8.6503 |
| TFR - Month 6 | 46.605 ± 9.5042 |
| TFR - Month 12 | 46.006 ± 8.6997 |
The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
| Participants | No Problems | Some Problems | Extreme Problems |
|---|---|---|---|
| Mobility — Number of participants | 22 | 4 | 0 |
| Self-Care — Number of participants | 25 | 1 | 0 |
| Usual Activities — Number of participants | 21 | 5 | 0 |
| Pain/Discomfort — Number of participants | 12 | 13 | 0 |
| Anxiety / Depresssion — Number of participants | 20 | 6 | 0 |
The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
| Participants | No Problems | Some Problems | Extreme Problems |
|---|---|---|---|
| Mobility — Number of participants | 23 | 8 | 0 |
| Self-Care — Number of participants | 31 | 0 | 0 |
| Usual Activities — Number of participants | 23 | 7 | 1 |
| Pain/Discomfort — Number of participants | 18 | 11 | 1 |
| Anxiety / Depresssion — Number of participants | 21 | 10 | 0 |
The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
| Participants | No Problems | Some Problems | Extreme Problems |
|---|---|---|---|
| Mobility — Number of participants | 19 | 8 | 0 |
| Self-Care — Number of participants | 28 | 0 | 0 |
| Usual Activities — Number of participants | 23 | 4 | 0 |
| Pain/Discomfort — Number of participants | 17 | 9 | 2 |
| Anxiety / Depresssion — Number of participants | 19 | 8 | 0 |
The EuroQol Five Dimensional Three-level questionnaire (EQ-5D-3L) comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
| Participants | No Problems | Some Problems | Extreme Problems |
|---|---|---|---|
| Mobility — Number of participants | 7 | 3 | 0 |
| Self-Care — Number of participants | 10 | 0 | 0 |
| Usual Activities — Number of participants | 10 | 0 | 0 |
| Pain/Discomfort — Number of participants | 5 | 4 | 1 |
| Anxiety / Depresssion — Number of participants | 8 | 2 | 0 |
The EuroQol Five Dimensional Three-level questionnaire (EQ-5D-3L) comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point
| Participants | No Problems | Some Problems | Extreme Problems |
|---|---|---|---|
| Mobility — Number of participants | 4 | 1 | 0 |
| Self-Care — Number of participants | 5 | 0 | 0 |
| Usual Activities — Number of participants | 4 | 1 | 0 |
| Pain/Discomfort — Number of participants | 1 | 4 | 0 |
| Anxiety / Depresssion — Number of participants | 3 | 2 | 0 |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment or last day in TFR Phase up to approximately 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib | 0/59 (0%) | 19/59 (32.2%) | 59/59 (100%) |
| Event | Nilotinib |
|---|---|
| Abdominal painGastrointestinal disorders | 2/59 |
| Cardiac failureCardiac disorders | 1/59 |
| Coronary artery diseaseCardiac disorders | 1/59 |
| Myocardial infarctionCardiac disorders | 1/59 |
| Pericardial effusionCardiac disorders | 1/59 |
| Hypoaesthesia oralGastrointestinal disorders | 1/59 |
| Small intestinal obstructionGastrointestinal disorders | 1/59 |
| Chest discomfortGeneral disorders | 1/59 |
| Chest painGeneral disorders | 1/59 |
| Device embolisationGeneral disorders | 1/59 |
| Event | Nilotinib |
|---|---|
| FatigueGeneral disorders | 23/59 |
| ConstipationGastrointestinal disorders | 17/59 |
| RashSkin and subcutaneous tissue disorders | 16/59 |
| HeadacheNervous system disorders | 14/59 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/59 |
| Abdominal painGastrointestinal disorders | 11/59 |
| NauseaGastrointestinal disorders | 11/59 |
| Lipase increasedInvestigations | 11/59 |
| PruritusSkin and subcutaneous tissue disorders | 11/59 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 10/59 |
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 55.5 ± 12.44 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 13 |
| Male | 19 |
| Race/Ethnicity, Customized(participants) | Overall |
|---|---|
| Caucasian | 25 |
| Black | 2 |
| Other | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2013 to primary completion in Sep 2018, 61 months.
Results were first posted in Mar 2020, 1 year 5 months after primary completion.
Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 61 months is above that.
Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →